CRISPR Therapeutics AG (CRSP) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    CRISPR Therapeutics AG

    NASDAQ: CRSP · Real-Time Price · USD
    61.67
    1.35 (2.24%)
    At close: Sep 26, 2025, 3:59 PM
    62.20
    0.86%
    After-hours: Sep 26, 2025, 07:56 PM EDT

    CRISPR Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 35M 371.21M 436K 913.08M
    Cost of Revenue
    		 110.25M 130.25M 110.25M 17.95M
    Gross Profit
    		 -75.25M 240.96M -109.81M 895.13M
    Operating Income
    		 -466.57M -222.54M -673.16M 373.53M
    Interest Income
    		 n/a n/a n/a n/a
    Pretax Income
    		 -362.67M -150.72M -650.5M 379.53M
    Net Income
    		 -366.25M -153.61M -650.17M 377.66M
    Selling & General & Admin
    		 72.98M 76.16M 102.46M 102.8M
    Research & Development
    		 320.65M 387.33M 461.64M 438.63M
    Other Expenses
    		 110.25M -1.21M -762K -1.88M
    Operating Expenses
    		 503.88M 462.29M 563.35M 539.55M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 501.57M 593.74M 673.6M 539.55M
    Income Tax Expense
    		 3.59M 2.89M -325K 1.87M
    Shares Outstanding (Basic)
    		 84.36M 79.22M 77.75M 75.95M
    Shares Outstanding (Diluted)
    		 84.36M 79.22M 77.75M 80.39M
    EPS (Basic)
    		 -4.34 -1.94 -8.36 4.97
    EPS (Diluted)
    		 -4.34 -1.94 -8.36 4.70
    EBITDA
    		 -447.31M -202.7M -648.99M 391.48M
    EBIT
    		 -466.57M -222.54M -673.16M 373.53M
    Depreciation & Amortization
    		 19.26M 19.84M 24.17M 17.95M

    Add to Watchlist